Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022

on Monday, 7 July 2014 include new market research report " Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update: Industry Size, Shares, Growth, Analysis, Trends And Forecast" to its huge collection of research reports.

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations.

Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations.

This Event-Driven Update was published in response to major events that occurred during the first quarter of 2014 that will result in the failure of several premium-priced agents to launch in the US and global markets during the forecast period. These agents include Pfizers dacomitinib and Boehringer Ingelheims nintedanib in the US, and Roches MetMab (onartuzumab) and GSKs MAGE-A3 immunotherapy in the global markets.


Key Questions Answered:

  • The NSCLC market will become increasingly crowded during the forecast. How will the first and second lines of therapy be impacted by the launch of new therapies?
  • How will the failure of dacomitinib and nintedanib to launch in the US affect global market growth? What effect will the failure to launch of MetMab (onartuzumab) and the MAGE-A3 immunotherapy in the nine major markets have on global market dynamics?
  • How will the increasing stratification of patient populations by biomarkers affect the treatment landscape?
  • The unmet needs of NSCLC patients are relatively high. What unmet needs will be addressed by the launch of new treatment options during the forecast period? What unmet needs will remain?
  • How will Alimta, Avastin, Iressa and Tarceva patent expirations affect overall market growth during the forecast?
  • How will increasing cost consciousness among European reimbursement authorities affect market growth in the 5EU?

Browse More related reports to Pharmaceuticals at:

Reasons to buy:

  • Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NSCLC therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Forecast drug sales in the global NSCLC therapeutics market from 2012-2022.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.

About Us:

ResearchMoz ( ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.

For More Information Kindly Contact: 
Mrs.Sheela AK
Toll Free: 866-997-4948


Post a Comment